Thirty-three eyes of 22 patients with primary open-angle glaucoma or severe ocular
hypertension had topical timolol maleate added to their maximally tolerated medical …

• Eighteen patients with glaucoma with a mean intraocular pressure (IOP)±SD of 28.7±5.5
mm Hg who were receiving maximum-tolerated antiglaucoma therapy were given 0.5 …

In an eight-week study, timolol maleate ophthalmic solution 0.25% was administered twice
daily with either pilocarpine 2% four times a day, epinephrine 2% twice a day, carbachol …

• The clinical courses of 41 patients who received timolol maleate for experimental protocols
were reviewed. We re-evaluated the conditions of 17 patients with the elevated pressures of …

We treated 20 patients who had primary open-angle glaucoma with either 0.25% or 0.5%
timolol for nine weeks. Once-daily administration of timolol significantly reduced intraocular …

The results of a 12-month blind randomised trial comparing the intraocular pressure
lowering effect of timolol 0.25% with timolol 0.5% are presented. 27% of patients (22% of …

Of 145 patients registered for an investigation of timolol, 27 patients were dropped for
unrelated reasons. Among the remaining 118 patients (212 eyes), a significant reduction in …

This paper reports a 200-week-long study of the efficacy of timolol maleate ophthalmic
preparations. At centres across Canada 117 patients were studied according to a rigid …

Timolol was used by 37 glaucoma patients from 1 to 18 months. Of those 37 patients, 31
used timolol for three months or longer and 7 used timolol for over one year. Timolol …

Thirty‐two eyes from 19 patients with either capsular glaucoma, pigmentary glaucoma or
primary open angle glaucoma were given topical timolol and followed through a 3–6 months …